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Abstract
Objective: We aimed to detect novel in vitro effects of clopidogrel on platelets by assessment of the following parameters: 
malondialdehyde, glutathione, nitrite, aggregation response, and expressions of P-selectin, fibrinogen, apolipoprotein A1, 
apolipoprotein B, and phosphatidylserine.
Materials and Methods: Platelets were obtained from healthy (n: 9) and hyperlipidemic (n: 9) volunteers. Expressions of 
P-selectin, fibrinogen, apolipoproteins A1/B and phosphatidylserine with and without clopidogrel were assayed by flow 
cytometry. Malondialdehyde, glutathione, aggregation and nitrite levels were also assayed. 
Results: Without clopidogrel, the baseline values of platelet aggregation, malondialdehyde, and expressions of P-selectin, 
fibrinogen and phosphatidylserine were significantly higher, whereas nitrite and expression of apolipoproteins A1/B were 
significantly lower in hyperlipidemics than in the healthy group. In both groups, clopidogrel significantly reduced aggrega-
tion and expression of fibrinogen, but it elevated nitrite levels. Clopidogrel significantly decreased P-selectin and phospha-
tidylserine expression and malondialdehyde but increased expressions of apolipoproteins A1/B only in hyperlipidemics. 
Conclusion: It seems that clopidogrel has some new in vitro antiplatelet effects. The present study is a basic in vitro study 
to suggest new insights into the effects of clopidogrel on platelet functions. 
(Turk J Hematol 2010; 27: 99-108)
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Özet
Amaç: Klopidogrelin trombositler üzerinde yeni in vitro etkilerini tayin etmek: Malondialdehit, glutatyon, nitrit, aggregasyon 
cevabı, P-selektin, fibrinojen, apolipoprotein A1, apolipoprotein B ve fosfatidilserin ekspresyonları. 
Yöntem ve Gereçler: Sağlıklı (n: 9) ve hiperlipidemik (n: 9) olgulardan trombositler elde edildi. Klopidogrelli ve klopidogrel-
siz trombositlerde P-selektin, fibrinojen, apolipoprotein A1, apolipoprotein B ve fosfatidilserin ekspresyonları flow sitometre 
ile tayin edildi. Malondialdehit, glutatyon, aggregasyon ve nitrit seviyeleri de tayin edildi. 
Bulgular: Klopidogrel yokluğunda, hiperlipidemililerde kontrollere göre trombosit agregasyonu, malondialdehit, P-Selektin, 
fibrinojen ve fosfatidilserin ekspresyonunun başlangıç değerleri yüksek; bununla birlikte nitrit, apolipoprotein A1 ve apoli-
poprotein B ekspresyonlarınınki ise daha düşüktü. Her iki grupta, klopidogrel anlamlı düzeyde aggregasyonu ve fibrinojen 
ekspresyonunu azalttı, fakat nitrit seviyelerini artırdı. Klopidogrel sadece hiperlipidemililerde P-selektin ve fosfatidilserin 
ekspresyonunu ve malondialdehiti azalttı ancak apolipoprotein A1 ve apolipoprotein B ekspresyonlarını artırdı. 
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Atherothrombotic events due to vasoactivity, inflammation 
and also lipids may affect platelet function. Antiplatelet therapy 
is one of the most effective therapies for treatment of athero-
thrombotic and other associated diseases [1-4].
Platelet composition and function abnormalities in patients 
with hyperlipoproteinemia suggest that the circulating levels 
of lipids influence the platelet markers such as P-selectin [5]. 
In fact, it has been reported that increased low-density lipo-
protein (LDL), especially oxidized-LDL, reduces platelet and 
macrophage nitric oxide (NO) synthase expression, and thus 
platelet activation increases [6]. There is some evidence of 
these lipoproteins interacting with platelets via specific recep-
tors. It has been reported that there are high-density lipopro-
tein (HDL) and LDL binding sites on platelets, and those 
binding sites are reduced in familial hyperlipidemia [7,8]. In 
our previous study, we had detected that apolipoprotein-A1 
(anti-apo-A1) was able to bind to the platelet surface indicat-
ing the presence of apo-A1 binding sites on platelets by a 
flow cytometric method [9].
On the other hand, the expression of P-selectin, fibrinogen, 
glycoprotein (Gp) IIb/IIIa, and circulating platelet-derived mic-
roparticles (PDMPs) on platelets are used as clinical markers 
for platelet activation status in several disorders including 
hyperlipidemia [10-13]. Additionally, occurrence of apoptosis-
like events in platelets has been confirmed by in vivo and in 
vitro studies. Phosphatidylserine (PS) appears on the outer cell 
membranes during the early stages of apoptosis. PS exposure 
serves as a procoagulant stimulus and a signal for phagocytic 
clearance of apoptotic cells including platelets as well as being 
an activation marker [14-16]. Reactive oxygen species have a 
number of important pro-atherogenic effects such as oxidation 
of LDL and activation of platelets [17]. It has been reported that 
in vivo platelet “release reaction” and malondialdehyde (MDA) 
formation are increased in hyperlipidemic patients [18]. 
The target of most of the antiplatelet treatments is either 
platelet agonist receptors or platelet fibrinogen receptor 
GpIIb/IIIa [19]. Several antiplatelet drugs have been devel-
oped to inhibit platelet activity in acute thrombotic events 
[20]. Clopidogrel, which is a thienopyridine derivative, blocks 
platelet aggregation irreversibly by binding to P2Y12 , one of 
the adenosine diphosphate (ADP) receptors on platelets. 
Clopidogrel affects GpIIb/IIIa complex activation. Several 
studies have reported that the essential action of thienopyri-
dine derivatives occurs upon their derivatization in the liver 
[21-23]. However, various other studies have reported that 
clopidogrel had different in vitro antiplatelet effects on plate-
lets [24-26]. Although those studies have been carried out in 
different mediums such as whole blood, isolated platelets or 
platelet-rich plasma (PRP), the consensus of those studies is 
that hepatic biotransformation is not required for platelet inhi-
bition by clopidogrel, which seems contrary to most of the in 
vivo studies. Considering those studies, our aim was to inves-
tigate some new effects of clopidogrel on platelets, which 
were obtained from healthy and hyperlipidemic volunteers 
under in vitro conditions. The novel in vitro effects of clopido-
grel on the following parameters were investigated: apo A 
and apolipoprotein B (apo B) binding sites, expression of 
P-selectin and fibrinogen, PS exposure on the surface of 
platelets, aggregation response, MDA, glutathione (GSH) and 
nitrite levels in platelets. We think that our findings obtained 
under in vitro conditions will be useful in future studies to 
determine new targets for the drug. 
Materials and Methods
Subjects and Blood Sampling 
The study group consisted of 9 hyperlipidemic (7 males 
and 2 females) patients and 9 normolipidemic, age- and sex-
matched control subjects (6 males and 3 females). This study 
was performed in accordance with the Declaration of Helsinki. 
Written evidence of informed consent was obtained from 
each participant. Table 1 shows some characteristics of the 
Sonuç: Görüldüğü üzere klopidogrel bazı yeni in vitro antiplatelet etkilere sahiptir. Bu çalışma, trombosit fonksiyonları üzeri-
nde klopidogrelin etkilerine yeni bir bakış açısı sağlayan temel in vitro bir çalışmadır.
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Table 1. Some characteristics of the healthy and hyperlipidemic 
groups
  Healthy Group  Hyperlipidemic Group
n 9  9
Age, years  46 ±4.65  49±6.96 (NS)
Male/Female 6/3  7/2  (NS)
BMI, kg/m2 24.11±3.21  28.55±2.92*
T-CHO, mmol/L  4.66±0.20  7.70±0.36***
LDL-C, mmol/L  2.98±0.24  5.50±0.31***
VLDL-C, mmol/L  0.57±0.22  1.13±0.13***
TG, mmol/L  1.32±0.18  2.44±0.23***
HDL-C, mmol/L  1.51±0.25  0.94±0.14**
BMI: Body mass index; T-CHO: Total cholesterol; LDL-C: Low density lipoprotein cholesterol; 
VLDL-C: Very low density lipoprotein cholesterol; HDL-C: High density lipoprotein cholesterol; TG: 
Triglyceride; * p<0.05, ** p<0.01, *** p<0.001, NS: not significant
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levels were within the normal ranges. Exclusion criteria were: 
secondary hyperlipidemia (renal, liver, thyroid and cardiovas-
cular disease), fasting glucose > 6.1 mmol/L, HbA1c (%) > 6, 
alcohol consumption, smoking, and use of anti-platelet, anti-
coagulant or lipid-lowering drugs within the previous eight 
weeks. All subjects were normotensive (<140/90 mmHg) and 
fasting glucose levels were in the normal range. The levels of 
total cholesterol (T-CHO) and triglyceride (TG) were deter-
mined by enzymatic methods using test kits with a Hitachi 
917 analyzer. HDL-cholesterol (C) was measured by the dex-
tran sulfate-Mg+2 precipitation method. LDL-C and very low-
density lipoprotein (VLDL)-C were calculated by the formula 
of Friedewald. 
Fasting venous blood samples were obtained with a 
21-gauge butterfly needle from healthy and hyperlipidemic 
volunteers. Whole blood was collected into tubes containing 
3.2% sodium citrate and used for flow cytometric analysis. 
PRP was used for aggregation and other analysis. 
Drug 
Clopidogrel was obtained from Sanofi Synthelabo, France. 
In the reactions, 10 μM clopidogrel was used at a final concen-
tration, which is close to the therapeutic concentration in 
human plasma reported by Cruz et al. [24]. 
Flow Cytometric Analysis
Expressions of P-selectin and fibrinogen on the surface 
of platelets were assayed according to the modified flow 
cytometric analysis method of Shattil et al. [27] as previ-
ously described. Briefly, citrated whole blood was diluted 
(1:10) in phosphate-buffered saline (PBS) (8 mM NaH2PO4, 
5 mM KCl, 125 mM NaCl, 5 mM glucose and 0.5 g/L albu-
min) and mixed gently. Whole blood (50 μL) was incubated 
with clopidogrel (10 μM) for 5 min at 37oC. The following 
steps were not used so that platelet activation during the 
assay could be minimized: washing, centrifugation, gel filtra-
tion, and mixing vigorously. All blood samples were stimu-
lated with ADP (10 μM) for 5 min. Then, they were added to 
polypropylene tubes containing the appropriate amounts of 
fluorescein isothiocyanate (FITC)-labeled antibodies such as 
anti-CD62P-FITC (to detect platelet activation marker, 
P-selectin) (Immunotech, Coulter) or anti-fibrinogen-FITC (to 
detect platelet activation marker, platelet bound fibrinogen) 
(polyclonal rabbit antihuman fibrinogen-FITC, Dako 
Cytomation). The samples were incubated for 15 min at 
room temperature without stirring, and then an equal vol-
ume of 0.02 g/ml para-formaldehyde was added to stop the 
reaction. In parallel experiments, the same procedure was 
performed without addition of the drug. The samples were 
further diluted with PBS and kept in the dark at 4°C until 
flow cytometric measurement. 
Diluted whole blood samples (with or without the drug) 
were stimulated with ADP (10 μM) for 10 min to detect PS 
exposure (platelet early apoptosis) on the surface of the 
platelets. It has been reported that PS exposure on the surface 
of cells is commonly measured by flow cytometry of fluorescently 
labeled annexin V binding to these procoagulant phospholipids. 
Annexin V-FITC (25 μg/ml) (Immunotech Coulter) was added to 
the samples and the tubes were kept on ice for 10 min. Then, 
400 μL of ice-cold binding buffer (10 mM HEPES/NaOH (pH 
7.4) 140 mM NaCl, 2.5 mM CaCl2) was added to the blood 
samples, and flow cytometric analysis was performed. 
We used the same method in our previous study with a 
small modification for flow cytometric assay for apo-A1 and 
apo B, which were bound to the surface of platelets [9]. Diluted 
whole blood samples (with or without clopidogrel) were stimu-
lated with ADP (10 μM) for 5 min. Monoclonal antibodies 
(MoAbs) against apo-A1 or apo B were added (1/100 diluted 
as optimal Moab concentration). After 15 min incubation at 
room temperature in the dark, 5 μL of FITC-labeled secondary 
antibody was added to the tubes. Then, the tubes were mixed 
and incubated for 15 min at room temperature in the dark. The 
tubes were centrifuged and the cells were washed with PBS 
two or three times by centrifugation to remove unbound FITC-
labeled secondary antibody. Progression of the reaction was 
stopped by adding an equal volume of 0.02 g/ml para-formal-
dehyde. The samples were diluted with PBS and kept at 4°C 
prior to flow cytometric analysis. 
All the samples, which were prepared as described 
above, were analyzed on a Beckman Coulter, EPICS XL-MCL 
flow cytometer. The flow cytometer was equipped with a 488 
nm argon ion laser. The platelet population was identified by 
forward scatter for cell size and by side scatter for cell granu-
larity. Alignment of the instrument was checked by calibration 
beads daily. An electronic bitmap was placed around the 
platelet population and CD41a-FITC was used to form a gate. 
The results were expressed as the percentage of antibody-
positive platelets. Nonspecific and background fluorescence 
was determined by the use of FITC conjugated immuno-
globulin G (IgG). Fifty thousand platelets were counted in 
each tube. 
Platelet Aggregation
Platelet-rich plasma and platelet-poor plasma (PPP) were 
prepared by differential centrifugation. PRP was obtained by 
centrifugation of citrated whole blood for 8 min at 1500 rpm. PPP 
was obtained by centrifugation of PRP for 10 min at 3500 rpm.
Clopidogrel was incubated with PRP (500 μL) for 10 min. 
ADP (Chronolog, final concentration 5 μM) was used to stimu-
late platelet aggregation. The aggregation responses were 
assayed on Chronolog-Lumi aggregometer and recorded as 
the mean percentage of maximum platelet aggregation both 
with and without clopidogrel. 
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Platelet-rich plasma (1.5 ml) was incubated with clopidogrel 
(10 μM) at 37°C for 15 min. After centrifugation at 10,000 rpm 
for 15 min, the platelet pellet was obtained. After washing twice 
with Tris-NaCl EDTA buffer, the platelet pellet, which was 
treated either with or without clopidogrel, was suspended in 
distilled water. It was frozen and thawed four times and then 
centrifuged at 10,000 rpm for 15 min. The supernatant was 
used for GSH assay and 15% metaphosphoric acid was 
added according to the Mergel and Anderman method [28]. 
The results were expressed as microgram per 109 platelets. 
The precipitate was solubilized with Tris-NaCl buffer con-
taining 1% Triton X-100 for 8 h and then centrifuged. After 
solubilization, platelet crude membrane MDA levels were 
assayed as a product of lipid peroxidation in supernatants with 
thiobarbituric acid reactive substances (TBARS) method [29]. 
The results were expressed as nmoL/mg crude protein. The 
protein concentration was determined according to the 
Bradford method and bovine serum albumin was used as the 
standard [30]. The sensitivities of GSH and MDA are as follows: 
GSH: 0.4-100 μM,and MDA: 0.1 μM.
Nitrite Assay 
After centrifugation of PRP at 10,000 rpm for 15 min, the 
platelet pellet was obtained and washed twice with PBS buffer. 
The washed platelets were incubated with clopidogrel (10 μM) 
and 1.44 mmol/L NADPH for 1 h at 37°C. Then, each sample, 
treated with or without clopidogrel, was incubated for 1 h at 
37°C after the addition of 20 mU nitrate reductase, which 
reduced nitrate to nitrite. The platelets were frozen and thawed 
four times. After centrifugation, the supernatant was allowed to 
react with Griess reagent to form a chromophore; its absorp-
tion was measured subsequently at 546 nm. Sodium nitrite 
(0.2 to 4 μM) was used as the standard [6]. The sensitivity of 
nitrite was 2 μM. 
Statistical Analysis
The results were presented as mean ± SD. Mean differ-
ences between the healthy and patient groups were calcu-
lated with the nonparametric Mann-Whitney U test. Analyses 
before and after the drug addition were compared using the 
Wilcoxon signed-rank test. Statistical analyses were per-
formed with SPSS software. P values <0.05 were considered 
significant. 
Results
Figure 1 shows Flow cytometric histograms of antibodies 
(ApoA, Apo B, CD62P-, antifibrinogen, annexinV) in a hyperlip-
idemic patient with or without clopidogrel. Figure 2A shows the 
expression of fibrinogen and Figure 2B shows the expression 
of P-selectin on the ADP-stimulated platelet surface. Before 
clopidogrel was added, there were significant differences in the 
expression of both P-selectin (%) and fibrinogen (%) between 
the hyperlipidemic and the healthy groups. In both groups, the 
expression of fibrinogen (%) was significantly decreased after 
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Figure 1. Flow cytometric histograms of antibodies (ApoA, Apo B, CD62P-, antifibrinogen, annexinV) in a hyperlipidemic patient with or without 
clopidogrel. Mean channel values were used for the evaluation of negative and positive results. An unstained sample and another sample com-
bined with related monoclonal antibodies (without clopidogrel) were used as negative controls. More than 20% shift in channel numbers is 
regarded as a cut off point for the negative/positive results
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after clopidogrel
100 101 102 103 104
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after clopidogrel
100 101 102 103 104clopidogrel; however, clopidogrel significantly decreased 
P-selectin expression on platelets only in hyperlipidemics. 
Phosphatidylserine exposure with ADP-stimulated platelets 
is shown in Figure 3. Before clopidogrel, there were significant 
differences in PS exposure (annexin V) between the hyperlipid-
emic and the healthy groups. After clopidogrel, platelet PS 
exposure (annexin V) was significantly decreased in the hyper-
lipidemic group, but not in the healthy group. 
We measured the levels of MDA and GSH in platelets. 
Figure 4A shows the levels of MDA and Figure 4B shows the 
levels of GSH before and after clopidogrel in the healthy and 
hyperlipidemic groups. Before clopidogrel, there were signifi-
cant differences in the levels of MDA between the hyperlipid-
emic group and the healthy group, but not in GSH levels. MDA 
levels significantly decreased after clopidogrel in the hyperlipid-
emic group. On the other hand, GSH levels remained 
unchanged after clopidogrel in both groups 
Platelet aggregation responses before and after clopidogrel 
are shown in Figure 5. Before clopidogrel, there were signifi-
cant differences in the aggregation (%) status between the 
hyperlipidemic patients and the healthy volunteers. After clopi-
dogrel, platelet aggregation response significantly decreased in 
both healthy and hyperlipidemic groups (Figure 5A). Figure 5B 
shows the aggregation responses before and after clopidogrel 
in the hyperlipidemic group.
Nitrite levels in platelets are shown in Figure 6. Before 
clopidogrel, there were significant differences in the levels of 
nitrite between the hyperlipidemic and the healthy groups. In 
both groups, platelet nitrite levels significantly increased after 
clopidogrel. 
Figure 7A shows the expression of platelet apo-A1 before 
and after clopidogrel in the hyperlipidemic group and healthy 
volunteers. Before clopidogrel, there were significant differ-
ences in the expressions of apo-A1 and apo B on the platelet 
surface between the hyperlipidemic patients and the healthy 
group. The expression of platelet apo-A1 significantly increased 
after clopidogrel in the hyperlipidemic group, but did not 
change in the healthy group. 
Figure 7B shows the expression of platelet apo B before 
and after clopidogrel in the hyperlipidemic and healthy groups. 
The apo B expression on the platelet surface significantly 
increased after clopidogrel in the hyperlipidemic group, but did 
not change in the healthy group. 
Discussion
It has been reported that circulating activated platelets and 
increased thrombotic risk are related to many cardiovascular 
events such as angioplasty, stroke, diabetes mellitus, and 
hyperlipidemia [31-34]. In the present study, using a flow cyto-
metric method, we found that both P-selectin and fibrinogen 
expressions on the surface of platelets were significantly higher 
in the hyperlipidemic group compared to the healthy group. In 
our previous study, we had detected that the receptor num-
bers of GpIIb/IIIa, GpIIIa and P-selectin were significantly 
higher in hyperlipidemic patients [12]. In our present study, we 
confirmed our previous findings indicating that platelets are 
activated in the circulation in hyperlipidemic patients. 
In this study, we also observed that PS exposure, lipid per-
oxidation and aggregation response of platelets were all high-
er, whereas platelet nitrite levels were lower in hyperlipidemics 
than in the healthy group. It has been shown that increased PS 
exposure is an important signal of early apoptosis, platelet 
activation and procoagulant stimulus [14-16,35,36]. The 
increase of PS exposure, which we observed in this study, may 
be related to increased oxidative stress (high MDA levels), 
because oxidative stress is one of the mediators of apoptosis 
[37]. Due to the increasing platelet aggregation response and 
PS exposure, we can speculate that platelets from hyperlipid-
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Figure 2. Mean values for expressions of fibrinogen (A) and P-selectin (B) 
in platelets of different study groups. 
Normal: Platelets from the healthy group; HL: Platelets from the hyperlip-
idemic group
*** P <0.001 vs normal 
a, P <0.01 vs normal 
+, P <0.01 vs HL 
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+emic subjects are more susceptible to ADP and the apoptosis-
activation process. 
In fact, it has been reported that elevated LDL, espe-
cially oxidized-LDL, may reduce NO synthase expression in 
platelets and macrophages. Due to the decrease in NO, 
platelet activation and cellular production of oxygen radicals 
may increase [38]. The measurement of nitrite levels instead 
of NO has been used in several studies since it is an indirect 
indication of NO production. As it is known, when LDL is at 
high concentrations and when it is together with an agonist 
such as ADP (as in our study), it triggers platelet hyperactiv-
ity and vascular damage as an independent stimulant 
[39,40]. Therefore, in this study, both elevated plasma LDL 
levels and platelet low nitrite levels observed in the hyperlip-
idemic subjects may be some of the factors responsible for 
the increase in platelet activation, platelet lipid peroxidation 
and apoptosis. One of the platelet abnormalities, observed 
in the hyperlipidemic group, is the change in membrane 
receptor responses. It has been shown that patients with 
Figure 3. Mean values of annexin-V (PS exposure) in platelets of different 
study groups.
Normal: Platelets from the healthy group; HL: Platelets from the hyperlip-
idemic group
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cantly lower platelet LDL and HDL binding sites [7,8,41]. In 
our study, expressions of both apo B (also LDL) and apo A 
(also HDL) on platelets were lower in the hyperlipidemic 
patients. This is possibly related to the reactivity potential of 
platelets in the hyperlipidemic group. Based on our findings, 
the increase in platelet activation, apoptosis, oxidative sta-
tus (MDA), aggregation, altered platelet membrane binding 
features, and decreased platelet nitrite levels in hyperlipid-
emia might elevate thrombotic risk causing atherogenesis to 
progress. 
New risk assessment criteria for thrombosis and cardio-
vascular diseases [42,43] and new drugs [44,45] for inhibi-
tion of coagulation are very important research areas. 
Clopidogrel is a drug that has been used for the secondary 
prevention of atherothrombotic events related to ischemia 
[46]. Although there are many in vivo reports related to the 
effects of clopidogrel on platelet functions, there are also 
various reports about its in vitro effects on platelets [24-26]. 
In those in vitro studies, it was shown that hepatic biotrans-
formation is not required for platelet inhibition by clopido-
grel. According to the findings of the study of De La Cruz et 
al. [24], clopidogrel in vitro reduced ADP-induced platelet 
aggregation and increased endothelial NO production 
depending on dose. Arrebola et al. [25] showed that throm-
boxane B2 production and collagen-induced platelet aggre-
gation were inhibited, but prostacyclin synthesis did not 
change following in vitro incubation with clopidogrel. Weber 
et al. [26] reported that the in vitro inhibition of platelet 
aggregation by clopidogrel is selective for ADP and does not 
require hepatic bioactivation. Regarding their findings, the 
inhibitory effects of clopidogrel were selective for ADP 
because no inhibition of platelet aggregation was seen with 
collagen, thrombin or thromboxane A2. Additionally, they 
have shown that the antiaggregant activity of clopidogrel 
was associated with the platelets and was not dependent 
on the presence of the compound in the test buffer. They 
also discussed that platelets are capable of generating the 
putative active metabolite of clopidogrel. This possibility is 
supported by the time-dependence of platelet inhibitory 
actions of clopidogrel in their study. In rats, Savi et al. [47] 
reported that clopidogrel (40 mg kg−1) was less effective in 
hepatectomized rats as compared to normal control rats. In 
addition, clopidogrel did inhibit platelet aggregation in iso-
lated, blood-perfused rat livers. 
It seems that our results support some of their findings, 
but we have also observed some novel in vitro effects of 
clopidogrel. We found that in vitro clopidogrel significantly 
increased platelet nitrite levels in both hyperlipidemic and 
healthy groups. In vitro and in vivo studies show that clopido-
grel may stimulate NO production via a Ca-dependent way in 
different cells. Thienopyridines enhance endothelial NO pro-
duction, which influences vascular wall endothelial function, 
platelet function and inflammation [48]. In our study, the same 
mechanism may be responsible for the effects of clopidogrel 
on nitrite production. 
It was reported in a study that there is a significant 
decrease in fibrinogen binding to GpIIb/IIIa by an aspirin and 
clopidogrel combination and a reduction in platelet P-selectin 
expression by clopidogrel alone [49]. Similarly, in our study, in 
the presence of ADP, clopidogrel reduced the fibrinogen 
expression on the platelet surface, and thereby, presumably 
decreased the platelet activation in both groups. On the other 
hand,  in vitro addition of clopidogrel to platelets reduced 
increased P-selectin expression only in hyperlipidemic 
patients. Storey et al. [50] showed that clopidogrel and P2Y12 
receptor antagonist suppressed platelet aggregation, 
P-selectin expression and platelet-leukocyte conjugate for-
mation, whereas aspirin had no such inhibitory effect. In our 
study, we also observed that clopidogrel has reducing effects 
on PS exposure, MDA levels and platelet aggregation 
Figure 7. Mean values for expressions of apoA1 (A) and apoB (B) in 
platelets of different study groups. 
Normal: Platelets from the healthy group; HL: Platelets from the hyperlip-
idemic group
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the antiaggregant effect of thienopyridines is more potent 
when aggregation is induced with ADP than with collagen. 
Although in this study we have not enlightened the exact 
mechanism of clopidogrel, we have speculated on the pos-
sible mechanisms inspired from in vitro and in vivo studies. 
Clopidogrel may block ADP-induced platelet aggregation via 
G protein activation and inhibition of adenyl cyclase or it may 
be totally independent from these factors. At the same time, 
clopidogrel may impair the transmembrane migration of PS, 
and thus PS exposure reduces.
In conclusion, the present study is a basic in vitro study to 
suggest new insights into the effects of clopidogrel on platelet 
functions. We observed that platelets from hyperlipidemic 
subjects may be more susceptible to agonists, activation and 
apoptosis. Disturbed lipid metabolism in those subjects may 
lead to physiochemical changes in platelet response and 
consequently may result in altered expression of surface 
membrane proteins, apoA and apoB. Those events may con-
tribute to the atherosclerotic process by elevating thrombotic 
risk in hyperlipidemics. We have shown some novel effects 
(for example apo A and apo B binding sites on platelets) of 
clopidogrel under in vitro conditions. To our knowledge, there 
is no in vivo study related especially with the effects of clopi-
dogrel on those platelet binding sites. It seems that clopido-
grel, which is not subjected to biotransformation, especially 
affects hyperlipidemic platelets by reducing platelet throm-
botic response and by altering membrane specifications. We 
are hopeful that our findings obtained under in vitro condi-
tions can be used in further studies to determine new benefits 
or side effects of clopidogrel.
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